MRD Negativity and Lenalidomide Maintenance Therapy: The Possible Next Chapter in Multiple Myeloma Care

On this episode of ASTCT Talks, we sit down with Dilan Patel, MD, advanced BMT fellow at Washington University School of Medicine in St. Louis. Patel was the lead author on a paper that explored minimal residual disease negativity and lenalidomide maintenance therapy, and how those were associated with superior survival outcomes for patients with multiple myeloma.

Tags: astct, MRD, BMT, bone marrow transplant, bone marrow, measurable residual disease